Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.

Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA.

Mayo Clin Proc. 2006 Aug;81(8):1047-53. Review.

PMID:
16901028
2.

Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.

Vieillard MH, Maes JM, Penel G, Facon T, Magro L, Bonneterre J, Cortet B.

Joint Bone Spine. 2008 Jan;75(1):34-40. Epub 2007 Aug 31.

PMID:
17981488
3.

Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.

Cetiner S, Sucak GT, Kahraman SA, Aki SZ, Kocakahyaoglu B, Gultekin SE, Cetiner M, Haznedar R.

J Bone Miner Metab. 2009;27(4):435-43. doi: 10.1007/s00774-009-0047-9. Epub 2009 Feb 26.

PMID:
19240969
4.

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.

J Clin Oncol. 2005 Dec 1;23(34):8580-7.

PMID:
16314620
5.

Zoledronic acid : a review of its use in the management of bone metastases of malignancy.

Dhillon S, Lyseng-Williamson KA.

Drugs. 2008;68(4):507-34. Review.

PMID:
18318568
6.

Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).

Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J.

Acta Pol Pharm. 2002 Nov-Dec;59(6):478-82.

7.

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS; American Society of Clinical Oncology Bisphosphonates Expert Panel.

J Clin Oncol. 2002 Sep 1;20(17):3719-36.

PMID:
12202673
8.

[Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].

Neumann B, Gregersen H.

Ugeskr Laeger. 2006 May 22;168(21):2078-9. Danish.

PMID:
16768928
9.

Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.

Lobato JV, Maurício AC, Rodrigues JM, Cavaleiro MV, Cortez PP, Xavier L, Botelho C, Hussain NS, Santos JD.

J Plast Reconstr Aesthet Surg. 2008;61(1):99-106. Epub 2006 Sep 12.

PMID:
18068658
10.

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.

Marx RE, Sawatari Y, Fortin M, Broumand V.

J Oral Maxillofac Surg. 2005 Nov;63(11):1567-75.

PMID:
16243172
11.

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.

Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J.

Cancer Invest. 2002;20 Suppl 2:45-54. Review.

PMID:
12442349
12.

[Osteonecrosis of the jawbone as a side effect of intravenous treatment with bisphosphonates].

Schortinghuis J, Witjes MJ, Spijkervet KL, de Visscher JG.

Ned Tijdschr Geneeskd. 2007 Feb 3;151(5):314-8. Dutch.

PMID:
17326477
13.

Bisphosphonates and osteonecrosis of the jaw: a retrospective study.

Murad OM, Arora S, Farag AF, Guber HA.

Endocr Pract. 2007 May-Jun;13(3):232-8.

PMID:
17599853
14.

Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients.

Capalbo S, Delia M, Diomede D, Dargenio M, Chiefa A, Favia G, Liso V.

Int J Hematol. 2006 Jun;83(5):439-42.

PMID:
16787865
15.

[Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma].

Lund T, Gregersen H, Vangsted A, Marker P, Abildgaard N.

Ugeskr Laeger. 2009 Jan 5;171(1-2):50-2. Danish.

PMID:
19128568
16.

[Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].

Dalle Carbonare L, Bertoldo F, Lo Cascio V.

Reumatismo. 2009 Jan-Mar;61(1):54-64. Italian.

17.

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.

Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, Andriani A, D'Arena G, Balleari E, Pietrantuono G, Boccadoro M, Palumbo A; GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network.

Cancer. 2008 Oct 1;113(7):1588-95. doi: 10.1002/cncr.23783. Erratum in: Cancer. 2008 Nov 15;113(10):2835.

18.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
19.

Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.

Cafro AM, Barbarano L, Nosari AM, D'Avanzo G, Nichelatti M, Bibas M, Gaglioti D, Taroni A, Riva F, Morra E, Andriani A.

Clin Lymphoma Myeloma. 2008 Apr;8(2):111-6. Erratum in: Clin Lymphoma Myeloma. 2008 Aug;8(4):260. Barbarano, Luciana [added]; Nosari, Anna Maria [added]; D'Avanzo, Giovanna [added]; Nichelatti, Michele [added]; Bibas, Michele [added]; Gaglioti, Domenico [added]; Taroni, Alberto [added]; Riva, Francesco [added]; Morra, Enrica [added]; Andriani, Alessandro [added].

PMID:
18501105
20.

The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.

Kraj M, Pogłód R, Maj S, Owczarska K.

Acta Pol Pharm. 2006 Sep-Oct;63(5):450-2. No abstract available.

Supplemental Content

Support Center